Evidence map›Paper›PMID 35348189›Full record

ArticleInternational journal of oncology2022

Isoforms of the orphan nuclear receptor COUP‑TFII differentially modulate pancreatic cancer progression.

Simone Polvani, Sara Pepe, Sara Tempesti, Mirko Tarocchi, Giada Marroncini, Lapo Bencini, Elisabetta Ceni, Tommaso Mello, Lucia Picariello, Irene Simeone and 6 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Simone PolvaniGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Sara PepeCore Research Laboratory, Institute for Cancer Research and Prevention, I-50139 Florence, Italy.
Sara TempestiGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Mirko TarocchiGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Giada MarronciniEndocrinology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50139 Florence, Italy.
Lapo BenciniOncology General Surgery, Azienda Ospedaliero Universitaria Careggi, I-50139 Florence, Italy.
Elisabetta CeniGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Tommaso MelloGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Lucia PicarielloGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Irene SimeoneGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Cecilia GrapponeGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Gabriele DragoniGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, I-50139 Florence, Italy.
Elisa GiommoniMedical Oncology, Azienda Ospedaliero Universitaria Careggi, I-50139 Florence, Italy.
Stefano MilaniGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
Andrea GalliGastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, I-50134 Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of the nuclear receptor transcription factor (TF) COUP‑TFII is broadly associated with cell differentiation and cancer development, including of pancreatic ductal adenocarcinoma (PDAC), a devastating disease with one of the poorest prognoses among cancers worldwide. Recent studies have started to investigate the pathological and physiological roles of a novel COUP‑TFII isoform (COUP‑TFII_V2) that lacks the DNA‑binding domain. As the role of the canonical COUP‑TFII in PDAC was previously demonstrated, the present study evaluated whether COUP‑TFII_V2 may have a functional role in PDAC. It was demonstrated that COUP‑TFII_V2 naturally occurs in PDAC cells and in primary samples, where its expression is consistent with shorter overall survival and peripheral invasion. Of note, COUP‑TFII_V2, exhibiting nuclear and cytosolic expression, is linked to epithelial to mesenchymal transition (EMT) and cancer progression, as confirmed by nude mouse experiments. The present results demonstrated that COUP‑TFII_V2 distinctively regulates the EMT of PDAC and, similarly to its sibling, it is associated with tumor aggressiveness. The two isoforms have both overlapping and exclusive functions that cooperate with cancer growth and dissemination. By studying how PDAC cells switch from one isoform to the other, novel insight into cancer biology was gained, indicating that this receptor may serve as a novel possible target for PDAC management.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCOUP Transcription Factor IIEpithelial-Mesenchymal TransitionHumansMiceOrphan Nuclear ReceptorsProtein IsoformsCOUP Transcription Factor IIOrphan Nuclear ReceptorsProtein IsoformscancerCOUP‑TFIIepithelial to mesenchymal transitionnuclear receptorstem cell

Identifiers

PMID35348189
PMCPMC8997336
OpenAlexW4221044546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.